Harputluoglu M.Caliskan A.R.Akbulut S.2024-08-042024-08-0420220022-3085https://doi.org/10.3171/2021.5.JNS21109https://hdl.handle.net/11616/90424Autoimmune hepatitis is a chronic inflammatory disease of the liver that is characterized by circulating autoantibodies and elevated serum globulin levels. Liver transplantation may be required for patients with acute liver failure, decompensated cirrhosis, and hepatocellular carcinoma. Recurrence is defined as development of the same disease in the allograft following liver transplantation. Autoimmune hepatitis recurs in 36%-68% of the recipients 5 years after liver transplantation. De novo autoimmune hepatitis is the development of autoimmune hepatitis like clinical and laboratory characteristics in patients who had undergone liver transplantation for causes other than autoimmune hepatitis. Diagnostic work up for recurrent and de novo autoimmune hepatitis is similar to the diagnosis of the original disease, and it is usually difficult. Predniso(lo)ne with or without azathioprine is the main treatment for recurrent and de novo autoimmune hepatitis. Early diagnosis and treatment are vital for patient prognosis because de novo autoimmune hepatitis and recurrent autoimmune hepatitis cause graft loss and result in subsequent retransplantation if medical treatment fails. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.eninfo:eu-repo/semantics/openAccessAutoimmune hepatitisDe novo autoimmune hepatitisLiver transplantationRecurrence autoimmune hepatitisArticle1365127312773462486310.3171/2021.5.JNS211092-s2.0-85129950943Q1